Apellis Pharmaceuticals, Inc. (APLS) Tops Q3 EPS by 12c
(Updated - October 30, 2025 8:17 AM EDT)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of $1.67, $0.12 better than the analyst estimate of $1.55. Revenue for the quarter came in at $458.6 million versus the consensus estimate of $450.97 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.